Scientists have unveiled a computational design for a terahertz metasurface biosensor that combines five distinct materials—graphene, MXene, tungsten disulfide, gold, and copper—into a single multilayer architecture capable of detecting refractive-index changes associated with chikungunya virus infection. The study, published in Results in Optics by G. Arunachalam, A.R. Kalaiarasi, Giri.G. Hallur, and V. Parthasarathy, reports a numerically predicted sensitivity of 907 GHz per refractive-index unit, among the highest values reported for hybrid-material terahertz biosensors, and couples the electromagnetic design to an XGBoost machine-learning surrogate model that predicts sensor behavior with accuracies exceeding 99.8 percent.

Chikungunya virus is an enveloped, positive-sense single-stranded RNA alphavirus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes. While mortality remains low, generally below 0.1 percent, the broader public health burden arises from severe polyarthralgia that can persist for months or even years in a substantial fraction of patients across tropical and subtropical regions. With no approved antiviral therapy or licensed vaccine currently available, diagnostic accuracy sits at the center of clinical management and transmission control. Yet existing diagnostic tools face significant practical constraints, particularly in point-of-care and field settings.

Serological methods such as enzyme-linked immunosorbent assay suffer from cross-reactivity with related alphaviruses, including Ross River and O’nyong-nyong viruses, reducing diagnostic specificity. Real-time reverse transcription polymerase chain reaction offers high sensitivity during the acute phase but depends on laboratory infrastructure, trained personnel, and controlled sample handling. Virus isolation in cell culture provides confirmatory results but requires biosafety level-3 facilities and extended processing time. These limitations have motivated the search for rapid, label-free sensing approaches capable of operating at clinically relevant concentrations in decentralized environments.

The new work turns to the terahertz band, spanning roughly 0.1 to 10 THz, which lies between microwave and infrared regions of the electromagnetic spectrum. Terahertz radiation is non-ionising, with photon energies in the millielectronvolt range, allowing interaction with biological samples without causing ionising damage. Crucially, terahertz waves couple to low-frequency vibrational and rotational modes of biomolecules such as proteins, nucleic acids, and polysaccharides, producing measurable spectral features that support label-free detection. Because biological media including blood plasma and viral suspensions exhibit refractive-index variations in this domain, differences on the order of 0.01 to 0.02 refractive-index units can shift resonance frequency and field distribution when coupled to resonant sensing structures.

The proposed sensor is built around a periodically repeated square unit cell containing two identical square resonators, 2000 nanometers on a side, coated with tungsten disulfide—a two-dimensional transition metal dichalcogenide with strong light–matter interaction, high carrier mobility, and excellent dielectric confinement. This layer localizes the electric field in the sensing region and increases the interaction volume between the resonant field and the surrounding analyte. A pair of concentric circular rings, 3200 and 3800 nanometers in diameter and functionalized with MXene, surrounds the resonators, enhancing electromagnetic coupling, promoting efficient charge transport, and strengthening plasmonic interactions between resonator elements. An outer gold ring, 6000 nanometers in diameter, serves as the main plasmonic resonator supporting strong localized surface plasmon resonances with low optical loss. The entire multi-resonant assembly is embedded within a monolayer graphene sheet measuring 14,000 by 14,000 nanometers, which acts as a broadband absorber and a high-mobility charge transport medium whose electrically tunable chemical potential allows dynamic, active control of the resonance characteristics. Copper elements woven into the architecture provide supplementary conductive pathways that reinforce current distribution and coupling among the hybrid resonators. The structure rests on a silicon dioxide substrate, chosen for its low dielectric loss and mechanical robustness, which preserves the resonance quality factor.

The authors stress that the multilayer design is compatible with established microfabrication techniques. Fabrication would begin with a cleaned silicon dioxide substrate, followed by polymer-assisted transfer of monolayer graphene and thermal annealing. Gold and copper resonators can be deposited through electron-beam evaporation or magnetron sputtering with lift-off patterning, MXene rings through solution-based deposition, and the tungsten disulfide layer through chemical vapor deposition or thin-film transfer. With a unit-cell dimension of approximately 14 micrometers, the required feature sizes fall comfortably within conventional photolithography capabilities, and because fabrication imperfections remain far smaller than the operating terahertz wavelength, moderate tolerances are expected to have only limited influence on the electromagnetic response. For biosensing, the graphene surface could subsequently be functionalized with chikungunya-specific antibodies or aptamers using EDC/NHS or pyrene-based linker chemistries.

The electromagnetic modeling, performed in COMSOL Multiphysics, reveals a pronounced resonance at 0.355 THz, where electric-field simulations show the strongest and most spatially extensive enhancement. Varying the graphene chemical potential from 0.1 to 0.9 electronvolts produced dramatic modulation of the transmission contrast, which increased roughly 36-fold at the highest bias, from less than one percentage point to more than 27 percentage points, while peak transmission remained essentially unchanged above 98.6 percent. This asymmetric response—stable maxima paired with strongly modulated minima—arises because increasing chemical potential enhances graphene’s intraband conductivity, deepening resonant absorption through stronger light–matter interaction. The sensor also demonstrated remarkable angular robustness, maintaining peak transmittance above 97.8 percent across incident angles from 0 to 80 degrees, an important tolerance for realistic deployment where normal incidence cannot always be guaranteed.

Geometric optimization identified an outer circular resonator radius of 2500 nanometers and a square resonator side length of 2500 nanometers as the dimensions that maximize resonance strength, driving minimum transmittance down to approximately 65 to 67 percent and signifying optimal electromagnetic confinement within the active sensing region. When evaluated across refractive indices from 1.33 to 1.39, a range encompassing reported values for healthy plasma (approximately 1.35 RIU), healthy platelets (1.39 RIU), chikungunya-infected plasma (1.33 RIU), and infected platelets (1.38 RIU), the optimized configuration achieved a maximum sensitivity of 907 GHz/RIU, a figure of merit of 18.519 RIU⁻¹, a minimum detection limit of 0.061 RIU, a sensor resolution of 55.178, and a refractive-index resolution of 0.001 RIU. In comparative benchmarks against recently reported graphene- and hybrid-material-based terahertz biosensors—including graphene/copper/aluminum, graphene/silicon dioxide, MXene–graphene–black phosphorus, and graphene-integrated copper–silver designs—the proposed architecture’s sensitivity exceeded most published values, reflecting the synergistic field confinement produced by the five-material stack.

The machine-learning component addresses one of the central bottlenecks in metasurface development: the computational cost of repeated full-wave finite-element simulations during structural optimization. The team trained an XGBoost regressor, an ensemble method based on gradient-boosted decision trees, on simulation data covering incidence-angle variation and circular-ring dimension variation, using stratified sampling with 80 percent of data for training and 20 percent held out for independent testing, alongside five-fold cross-validation and grid-search hyperparameter optimization. The model captured more than 99.7 percent of response variance on unseen data, with mean absolute percentage errors below 0.162 percent and prediction accuracies from 99.838 to 99.959 percent. Acting as a computational surrogate, the trained model enables rapid interpolation across the design space without sacrificing the fidelity of the underlying electromagnetic model.

The authors are careful to frame the work as a computational proof-of-concept rather than an experimentally validated diagnostic. The sensor detects changes in the local dielectric environment surrounding the resonators, not viral particles or nucleic acids directly, and refractive-index sensing alone cannot intrinsically distinguish chikungunya from other viruses with similar dielectric properties. Analytical specificity in practice will depend on surface biofunctionalization with chikungunya-specific recognition molecules immobilized on the graphene or gold sensing surface. Future work will focus on device fabrication, biofunctionalization, calibration with reference refractive-index standards, experimental validation with clinically relevant plasma and platelet samples, and systematic evaluation of selectivity against related arboviruses—steps that would transform this numerically validated platform into a practical tool for rapid, label-free infectious disease diagnostics in the field.

Source

In a groundbreaking advancement for geriatric health assessment, researchers have unveiled a novel nonexercise approach to estimate cardiorespiratory fitness in older adults by utilizing seismocardiography (SCG). This innovative technology harnesses the subtle vibrations produced by cardiac activity, enabling precise monitoring of cardiovascular function without the need for physical exertion. As aging populations increase globally, the demand for accessible and reliable methods to evaluate heart and lung fitness has never been higher, making this development not only timely but also revolutionary.

Cardiorespiratory fitness traditionally requires exercise testing, involving treadmill or bicycle protocols that may pose risks or be impractical for elderly individuals with limited mobility or chronic conditions. The novel system employing SCG bypasses these challenges, offering a safe and feasible alternative that significantly minimizes patient burden. SCG captures micro-vibrations generated by the heart during each beat using sensitive accelerometers placed on the chest, translating mechanical cardiac events into quantitative data reflective of cardiovascular performance.

The study, led by Sundberg, Gates, and Boraxbekk among others, meticulously validated the use of SCG signals against established measures of cardiorespiratory fitness, such as VO2 max testing, across a diverse cohort of older adults. Their results demonstrated remarkable correlation, confirming that SCG can serve as a reliable proxy for exercise-based evaluations. This breakthrough is poised to transform clinical practice by facilitating widespread cardiovascular screening and monitoring in geriatric populations without exposing them to physical strain.

One of the pivotal technological advances underpinning this approach is the enhancement of signal processing algorithms that can accurately decipher the complex mechanical patterns of heart activity from SCG data. These algorithms filter noise and artifacts, isolating key features such as timing intervals between cardiac events that are indicative of cardiac output and fitness levels. By employing machine learning techniques, the research team optimized predictive models that link SCG metrics with cardiorespiratory capacity.

Beyond the impressive technical accomplishments, the application of SCG for fitness estimation aligns perfectly with the principles of personalized medicine. By providing continuous, noninvasive monitoring methods, clinicians can tailor interventions and lifestyle recommendations based on real-time fitness metrics, facilitating proactive management of cardiovascular health. This could substantially reduce the incidence of cardiovascular events, improve quality of life, and enhance longevity in aging adults.

Importantly, this methodology opens new avenues for remote health monitoring. The compact sensors utilized for SCG are lightweight, unobtrusive, and capable of wireless transmission, enabling integration with mobile health platforms. This may empower elderly individuals to measure their cardiorespiratory fitness regularly from the comfort of their homes. Such democratization of health data can lead to earlier detection of functional decline, prompt clinical interventions, and reduced healthcare costs.

From a physiological perspective, seismocardiography reveals intricate interactions governing heart mechanics, including myocardial contractility and valve function, which are directly tied to oxygen delivery and utilization — the cornerstone of cardiorespiratory fitness. This depth of insight surpasses conventional pulse or blood pressure monitoring, offering a richer dataset for comprehensive cardiovascular assessment. The capacity to obtain these insights passively without exercise expends minimal energy, crucial for frail patients.

The research also emphasizes the feasibility of SCG in monitoring dynamic changes in fitness over time. Whereas exercise-based testing reflects a snapshot requiring considerable effort and clinical resources, SCG’s accessibility permits serial measurements that track progression or regression in cardiorespiratory health. This longitudinal view enhances clinicians’ ability to evaluate treatment efficacy and adjust care plans appropriately.

Moreover, SCG technology exemplifies the convergence of biomechanics, biomedical engineering, and data science, epitomizing modern healthcare innovation. The fusion of robust sensors with advanced computational methods has produced a tool that transcends standard diagnostic modalities, offering a more comprehensive and patient-friendly option. This interdisciplinary synergy highlights the potential for future wearable technologies to expand their role in chronic disease management.

Addressing limitations, the study carefully acknowledges challenges such as variability in SCG signal quality due to anatomical differences and external factors. However, by employing adaptive algorithms and calibration protocols, the researchers have mitigated many of these issues, ensuring consistent performance across diverse patient profiles. Ongoing refinements aim to further enhance accuracy and user-friendliness, making broad clinical adoption realistic.

The implications of this research extend beyond geriatric cardiology, potentially influencing rehabilitation programs, sports science, and preventive medicine. With further validation, SCG could monitor athletes’ fitness without exhaustive testing or assist in evaluating pulmonary function in respiratory diseases. Its versatility underscores the broad applicability of biomechanical sensing in health monitoring paradigms.

In conclusion, the integration of seismocardiography for the nonexercise estimation of cardiorespiratory fitness in older adults marks a paradigm shift in cardiovascular health assessment. By circumventing the constraints of traditional exercise testing, this technology enables safe, efficient, and insightful evaluations that can be performed repeatedly and remotely. As the elderly demographic surges worldwide, the deployment of such innovative methods will be pivotal in optimizing healthcare delivery and promoting healthier aging.

The promise of SCG transcends mere technological novelty; it represents a compassionate approach to health evaluation that respects the physical limitations and safety of vulnerable populations. Empowering healthcare providers with precise, noninvasive tools enriches clinical decision-making and enhances patient outcomes. Looking ahead, continued research and integration with digital health ecosystems will likely establish seismocardiography as a cornerstone in the management of cardiovascular fitness.

Ultimately, the study spearheaded by Sundberg and colleagues not only broadens scientific understanding but also provides a tangible blueprint for implementing cutting-edge sensing technologies in everyday clinical practice. The synergy of engineering excellence, clinical insight, and patient-centric design encapsulates the future of medical innovation — one that prioritizes accessibility, safety, and actionable intelligence for all.

Subject of Research: Nonexercise estimation of cardiorespiratory fitness in older adults using seismocardiography.

Article Title: Seismocardiography for nonexercise estimation of cardiorespiratory fitness in older adults.

Article References:
Sundberg, M., Gates, A.T., Boraxbekk, C.J., et al. Seismocardiography for nonexercise estimation of cardiorespiratory fitness in older adults. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07771-6

Image Credits: AI Generated

In a groundbreaking departure from traditional approaches, researchers have unveiled a transformative perspective on EEG biomarkers for brain disorders, emphasizing a transdiagnostic dimensional framework that promises to revolutionize neuropsychiatric diagnostics and treatment. This pioneering study, conducted by Zebhauser, Heitmann, Henningsen, and colleagues, challenges decades-old conventions that pigeonhole brain disorders strictly according to categorical diagnostic criteria. Instead, it advocates for a more nuanced, continuum-based understanding of brain dysfunctions as reflected in electroencephalographic signals.

The conventional paradigm in neuropsychiatry has long relied upon discrete diagnostic labels—labels which often fall short in capturing the complex, overlapping symptomology exhibited across disorders such as schizophrenia, bipolar disorder, major depressive disorder, and anxiety disorders. Traditional EEG analyses have sought biomarkers confined within these diagnostic categories, leading to inconsistent results and limited clinical utility. The new study confronts these limitations by proposing that EEG biomarkers be analyzed through a dimensional lens that transcends categorical boundaries, enabling detection of underlying neural dysfunctions that span multiple disorders.

Central to this conceptual shift is the transdiagnostic approach, which posits that neurobiological aberrations are shared across different psychiatric conditions and manifest along spectrums of symptom severity and cognitive impairment. Through rigorous computational modeling and advanced signal processing applied to large EEG datasets, the research team delineated patterns of neural oscillatory activity and connectivity that correlate with continuous measures of cognitive and affective dysfunctions, irrespective of diagnostic categories. This approach underscores the shared neurophysiological substrates that traditional categorical classifications often obscure.

Methodologically, the study harnessed sophisticated machine learning algorithms to parse high-dimensional EEG data and extract signal features indicative of brain circuit dysregulation. By focusing on spectral power variations across frequency bands—delta, theta, alpha, beta, and gamma—as well as functional connectivity metrics between cortical networks, the researchers succeeded in identifying biomarkers reflective of symptom dimensions such as cognitive control deficits, emotional dysregulation, and sensory processing anomalies. These dimensions overlap across disorders, suggesting a common pathophysiological mechanism modulated along a continuum.

Importantly, the transdiagnostic dimensional framework enables more personalized and precise characterization of patients’ neural profiles. Instead of forcing diagnoses into rigid boxes, clinicians can now utilize EEG biomarkers to quantify an individual’s specific symptom constellation and severity in real-time. This precision facilitates tailored interventions that target dysfunctional brain networks directly, potentially enhancing treatment efficacy and reducing trial-and-error prescribing that often plagues psychiatric care.

The implications extend beyond diagnosis and treatment optimization. This novel EEG biomarker approach offers a powerful tool for preventative psychiatry by identifying at-risk individuals who may not yet meet full diagnostic criteria but exhibit measurable neural dysfunctions indicative of emerging disorders. By mapping these dimensional brain signatures early, clinicians can intervene preemptively, possibly altering disease trajectories before chronicity sets in.

Moreover, this paradigm fosters an integrative understanding of brain disorders as dynamic states rather than static labels. The EEG biomarkers track fluctuation in cognitive and affective states, capturing the temporal evolution of illness and response to therapy. Such temporally sensitive biomarkers pave the way for real-time monitoring of treatment response and disease progression via non-invasive methods, enhancing clinical decision-making and patient outcomes.

The study also confronts several technical challenges historically hindering EEG’s clinical translation. By developing robust preprocessing pipelines that mitigate artifacts and employing cross-validation techniques to ensure replicability of findings across diverse cohorts, the researchers set new standards for EEG research rigor. Their comprehensive methodology serves as a blueprint for future investigations aiming to unify neurophysiological data with psychiatric phenotypes in a clinically meaningful manner.

Furthermore, by adopting a transdiagnostic dimensional view, the research opens novel avenues for drug development. Pharmaceutical interventions can be engineered to target neural circuits and pathways implicated across multiple disorders, possibly leading to broader spectrum therapeutics with enhanced efficacy. This contrasts with the current trend of developing highly disorder-specific drugs, which may only benefit a subset of patients.

Underpinning this research is the recognition that brain disorders are multifactorial and multifaceted, involving intricate interactions between genetics, environment, and neural circuitry. The EEG biomarkers illuminated by this study reflect emergent properties of large-scale brain networks whose dysfunction cuts across traditional diagnostic divides. This holistic lens aligns with contemporary theories of brain function as distributed and dynamic, rather than localized and static.

Clinically, the transdiagnostic dimensional EEG biomarkers facilitate identification of subtypes within disorders, based on distinct neurophysiological profiles. Such stratification could improve prognostic accuracy and enable stratified clinical trials, ultimately accelerating discovery and application of targeted therapies. This personalized medicine approach marks a considerable leap in the field of psychiatry.

The study’s findings also resonate deeply with the Research Domain Criteria (RDoC) initiative advocated by the National Institute of Mental Health, which promotes research centered on fundamental dimensions of functioning rather than syndromic categories. The demonstrated EEG biomarkers provide tangible neurobiological correlates for RDoC constructs such as cognitive systems and arousal/regulatory systems, making a compelling case for their adoption in clinical and research frameworks.

Ethical and practical considerations emerge as these new EEG biomarkers are integrated into clinical practice. Ensuring equitable access to advanced neurodiagnostic technologies and protecting patient privacy with respect to neural data will be paramount. The authors acknowledge these issues and call for development of guidelines and safeguards alongside technological progress to maximize benefit and minimize harm.

This research heralds a new era in neuropsychiatry, where neural biomarkers derived from accessible EEG recordings become central to understanding, diagnosing, and treating brain disorders as dimensional phenomena. By transcending rigid diagnostic boundaries, this approach reflects the complex reality of brain function and dysfunction, offering hope for more effective, individualized care for millions worldwide impacted by mental illness.

In conclusion, the visionary framework proposed by Zebhauser and colleagues challenges entrenched conventions and illuminates a path forward marked by dimensional precision, cross-disorder integration, and clinically actionable EEG biomarkers. This work stands to reshape the landscape of psychiatric neuroscience and catalyze a shift toward truly personalized mental health care.

Subject of Research: EEG biomarkers and their application in a transdiagnostic dimensional framework for brain disorders

Article Title: Rethinking EEG biomarkers of brain disorders: a transdiagnostic dimensional view

Article References: Zebhauser, P.T., Heitmann, H., Henningsen, P. et al. Rethinking EEG biomarkers of brain disorders: a transdiagnostic dimensional view. Transl Psychiatry 16, 316 (2026). https://doi.org/10.1038/s41398-026-04187-z

Image Credits: AI Generated

DOI: 10 June 2026

A groundbreaking advancement in photonic technology promises to redefine the landscape of medical artificial intelligence (AI) diagnostics, as a research consortium led by Professor Han Zhang at Shenzhen University has unveiled a novel all-fiber photonic AI platform utilizing black phosphorus (BP)-based tunable modulators. This innovative approach, which hinges on photon-based computing, surmounts the intrinsic constraints posed by traditional electronic processors, delivering unprecedented energy efficiency and ultrafast performance crucial for real-time clinical decision-making.

The prevailing paradigm in medical AI, deeply reliant on electronic architectures such as GPUs, faces severe limitations related to energy consumption, heat dissipation, and processing latency. These factors collectively impede the integration of AI into time-sensitive diagnostic workflows and exacerbate systemic carbon footprints. Photonic computing, with its reliance on photons rather than electrons, offers dramatically accelerated data transmission speeds and parallelism through wavelength multiplexing, alongside near-zero heat generation. Until now, however, the practical implementation of photonic AI had been hampered by the bulkiness, inefficiency, and fabrication challenges synonymous with conventional optical modulators.

Professor Zhang’s team has ingeniously engineered an atomically thin van der Waals heterostructure by stacking black phosphorus and molybdenum disulfide (MoS2), leveraging the extraordinary optoelectronic properties of these 2D materials. This heterostructure is meticulously integrated onto a microfiber knot resonator (MKR), an ultra-fine looped optical fiber with a diameter narrower than a human hair. This configuration significantly intensifies the interaction between light and material, enabling modulation of the refractive index with minimal applied voltage, which shifts the light’s wavelength to encode computational information with remarkable precision and energy economy.

The fabrication process commences with mechanical exfoliation to obtain pristine BP/MoS2 bilayers, followed by a dry transfer technique to position these heterostructures onto the MKR. The MKR’s torsional geometry enhances evanescent field coupling, ensuring that the optical mode overlaps maximally with the active layered materials. To broaden the modulator’s linear response and suppress nonlinear distortions, the researchers incorporated a Ring-Assisted Mach–Zehnder Interferometer (RAMZI) design. This integration extends the operational voltage range, ensuring fidelity and robustness essential for medical-grade AI computations.

The team transcended single-device innovation by architecting a full all-fiber photonic neural network (PNN). By deploying two RAMZI modulators in tandem with a highly sensitive photoreceiver within a sophisticated time-division multiplexing schema, they realized a closed-loop, coherent computing unit capable of executing neural network operations entirely in the optical domain. This milestone substantiates the transition of photonic neural networks from theoretical constructs to viable, deployable platforms for clinical diagnostics.

Clinical performance validation was conducted in collaboration with esteemed hospitals. The PNN demonstrated expert-level diagnostic accuracy in two stringent medical tasks: detecting retinal detachment from B-scan ultrasound imagery and diagnosing hepatocellular carcinoma (HCC) using multiphase liver computed tomography (CT) scans. Diagnostic accuracy and specificity metrics paralleled those of seasoned radiologists, underscoring the system’s potential for integration into frontline healthcare.

Beyond accuracy, the photonic system showcased transformative efficiency advantages. While a conventional NVIDIA A100 GPU requires approximately 85 milliseconds to process a liver CT study, the photonic platform accomplished the same in a mere 0.8 milliseconds. Additionally, the energy expenditure per operation plummeted to an astonishing 0.608 femtojoules, a staggering 246-fold decrease compared to electronic counterparts consuming 150 femtojoules. This synergy of speed and efficiency paves the way for deploying AI diagnostics in resource-constrained or mobile medical environments like rural clinics and ambulances, dramatically expanding access to critical health services.

The system’s environmental implications cannot be overstated. Conventional AI’s sizable energy footprint contributes appreciably to healthcare’s carbon emissions. The BP/MoS2-based photonic platform fundamentally disrupts this model by combining ultrafast processing with near-negligible thermal dissipation, forging a sustainable pathway for green AI implementations in medicine. This breakthrough aligns with expanding global commitments to environmentally responsible technologies without sacrificing computational power.

Acknowledging the infancy of current implementations, the authors outline avenues for scaling. Presently limited to a single processing layer realized through two modulators, the system’s complexity and image resolution capacity necessitate expansion. A promising strategy involves wavelength-division multiplexing (WDM), exploiting the device’s ∼30 nm bandwidth resonances to channel up to 40 distinct wavelengths. This parallelism would amplify computational density approximately 40-fold while maintaining the existing clock rate, facilitating thousands of multiplications per network layer—an enhancement critical to tackling high-dimensional medical image data.

Device longevity and stability pose additional challenges, given the sensitivity of BP to environmental degradation. While the MoS2 layer affords interim encapsulation, the team plans industrial collaboration to pioneer large-scale protective coatings via atomic layer deposition of Al2O3 and scalable chemical vapor deposition processes. These advancements will bolster device durability, uniformity, and manufacturability, accelerating clinical adoption and commercial viability.

The study also signifies the maturation of fiber-based photonic neural networks into practical diagnostic platforms rather than experimental novelties. Optical fibers’ inherently low transmission loss (<0.2 dB/km), synergized with the modulator’s efficient 0.25 V·cm electro-optic response and expanded linear range, addresses critical bottlenecks impeding prior photonic computing endeavors. Consequently, the technology promises to empower future applications in drug discovery, genomics, and real-time clinical imaging with unmatched energy footprints.

The pioneering work led by Professor Han Zhang not only foregrounds interdisciplinary collaboration across physics, materials science, and biomedicine but also sets a precedent for industry-academia partnerships catalyzing the commercialization of ultrafast photonic devices poised to transform healthcare AI. As research progresses towards integrated multi-layer architectures and industrial encapsulation, the healthcare sector stands on the cusp of embracing a new generation of diagnostic tools that are faster, greener, and broadly accessible.

This heralds a paradigm shift where medical AI transcends the limitations inherent to electronic systems, embracing photon-driven computing as a sustainable, high-performance alternative that aligns with the twin imperatives of clinical excellence and environmental stewardship.

Subject of Research: People

Article Title: Tunable phosphorene modulators – accelerating medical diagnosis with ultra-efficient photonic platforms

News Publication Date: 28-May-2026

References:
Zhang, H., Liu, Y., Wang, H., Zhu, H., et al. (2026). Tunable phosphorene modulators – accelerating medical diagnosis with ultra-efficient photonic platforms. Opto-Electronic Advances. DOI: 10.29026/oea.2026.250332

Image Credits: Professor Han Zhang of Shenzhen University

Keywords: photonic computing, black phosphorus, molybdenum disulfide, van der Waals heterostructure, microfiber knot resonator, electro-optic modulator, photonic neural network, medical imaging AI, energy efficiency, wavelength-division multiplexing, ultrafast diagnostics, sustainable healthcare

In the rapidly evolving field of computational pathology, artificial intelligence (AI) has demonstrated remarkable potential across a broad spectrum of diagnostic applications. Despite the impressive advances achieved by foundation and multimodal AI models, the translation of these technologies from experimental prototypes to everyday clinical practice remains sporadic and limited. This phenomenon, often described as the “adoption paradox” of computational pathology, highlights a profound disconnect between technical capability and practical clinical integration. New research published in LabMed Discovery offers a thorough examination of this paradox, proposing a robust framework to navigate the complexities of AI deployment in pathology.

At the core of the study lies a comprehensive three-stage maturity model that systematically categorizes the translational journey of AI in pathology. This framework details the progression from initial algorithmic development to full institutional adoption, articulating the critical barriers and enabling pathways that characterize each phase. Stage one, termed “Algorithmic Capability,” centers on the development and validation of AI algorithms under retrospective conditions. However, here the barriers are significant: data heterogeneity, infrastructure instability, and the fragility introduced by variations in scanner technologies and data formats hinder robustness and reproducibility.

The study identifies that overcoming Stage one’s obstacles requires an “infrastructure-first” approach. This pathway prioritizes the establishment of vendor-neutral data formats and the implementation of automated quality control measures. By fostering multicenter benchmark baselines and utilizing federated learning techniques, developers can mitigate issues like scanner shift and manual quality-control dependencies, which currently limit algorithmic generalizability across diverse clinical environments.

Transitioning into Stage two, “System Integration,” the research highlights the necessity for prospective multisite validation as a gatekeeper to advance AI from the lab into live clinical workflows. Workflow disconnects—such as cognitive rhythm mismatch, automation bias, and scenario-dependent latency—pose significant barriers to embedding AI seamlessly in day-to-day pathology operations. These misalignments can erode clinical trust and reduce effective adoption, emphasizing the need for human-centered design.

To counter these challenges in Stage two, the report advocates for “workflow-embedded intelligence,” a paradigm shift that integrates AI tools directly into the clinical workflow with features like triage prioritization, assistive decision layers, uncertainty visualization, and frictionless human override mechanisms. Such intelligent design ensures that AI functions as a collaborative partner rather than a disruptive force, supporting pathologists’ expertise while providing transparent and actionable insights.

Stage three, “Institutional Adoption,” focuses on achieving sustained use backed by demonstrable workflow benefits, viable reimbursement models, and comprehensive governance frameworks. This stage confronts deeply rooted barriers around institutional trust, interpretability, legal liability, and emerging risks associated with generative AI technologies. The complexity of securing organizational buy-in reflects the multifaceted nature of health systems, where regulatory accountability and risk management weigh heavily on technology acceptance.

To facilitate institutional trust and long-term integration, the authors underscore the importance of “adaptive governance.” This approach combines machine learning operations (MLOps) for continuous monitoring and maintenance, shadow deployments to validate real-world performance, and the collection of real-world evidence. Institutional policies must evolve to include robust validation procedures, liability frameworks, and protocols that address the nuances of generative AI risks, all crucial for sustainable clinical AI applications.

The maturity model also contextualizes current AI products within this framework, mapping approved and research-stage systems to their respective levels of advancement as of early 2026. This mapping provides a practical diagnostic tool, enabling stakeholders to identify specific bottlenecks and tailor interventions that promote progression toward routine clinical adoption. The ability to systematically understand why certain AI applications stall at particular stages offers a new lens for developers, policymakers, and clinical users alike.

Importantly, this comprehensive review sheds light on the broader evolution of pathology AI itself — tracing its trajectory from specialized task-specific deep learning models to the burgeoning domain of agentic systems capable of multimodal integration. Such advancement brings promise for more holistic and context-aware diagnostic solutions but simultaneously raises challenges in validation and governance that must be addressed proactively.

The authors’ insights extend beyond technological innovation; they provide a strategic blueprint for reconciling AI’s groundbreaking potential with real-world healthcare complexities. By emphasizing infrastructure readiness, user-centric workflow design, and dynamic governance, this model aligns technical ambition with clinical realities, harmonizing diverse stakeholders’ needs and expectations.

In conclusion, this study represents a pivotal contribution to computational pathology’s ongoing AI revolution. Its detailed three-stage maturity framework captures the nuanced interplay of algorithm development, system embedding, and institutional acceptance, delineating actionable pathways to bridge the daunting gap between algorithmic promise and everyday clinical utility. As AI continues to reshape medical diagnostics, systematic and adaptive approaches like this will be essential to unlocking its full, sustainable impact on patient care worldwide.

Subject of Research: Artificial intelligence adoption in computational pathology and its clinical integration challenges

Article Title: Adoption paradox of artificial intelligence in computational pathology: a three-stage maturity model from algorithms to clinical integration

News Publication Date: 2-Jun-2026

Web References: http://dx.doi.org/10.1016/j.lmd.2026.100130

Image Credits: Lu Cai, Biwen Meng, Jie Huang, Guanyu Ding, Min Ju, Wenwen Wang, Shijie Deng, Liqin Lai, Jin Wang, Chunxue Yang, Miao Ruan, Shugong Xu, Chaofu Wang, Jingxin Liu, Qian Da

Keywords: Algorithms, Computational Pathology, Artificial Intelligence, Clinical Integration, Workflow Design, Infrastructure, Institutional Trust

Often hailed as “the window to the soul,” the human eye has long fascinated scientists and philosophers alike. However, beyond its poetic allure, emerging research suggests that the eyes provide a vital window into the health of the brain. A groundbreaking new study spearheaded by the University of Florida’s biomedical engineering department has unveiled a transformative approach to predicting Alzheimer’s disease risk factors by analyzing retinal photographs with cutting-edge deep learning algorithms. This development promises to revolutionize early detection and intervention for one of the most devastating neurodegenerative diseases.

Traditionally, diagnosing Alzheimer’s disease has been a challenge due to its insidious onset and prolonged development over decades. Most diagnostic protocols focus on detecting the disease in its later stages, by which time significant, irreversible brain damage has already occurred. Recognizing this limitation, Dr. Ruogu Fang and her interdisciplinary team leveraged advances in artificial intelligence and biomedicine to explore the retina—a part of the central nervous system accessible via non-invasive imaging—as a potential biosensor for Alzheimer’s risk.

The study capitalized on a rich database of over 40,000 retinal images collected from the UK Biobank, a comprehensive health resource with longitudinal patient data. Retinal photography is commonly conducted during routine eye exams, diabetes management, glaucoma monitoring, and cataract assessments. By harnessing these widely available, inexpensive images, the research team circumvented the need for costly, invasive, or logistically complex diagnostic tools such as MRI or PET scans, thus holding promise for scalable, population-wide screening.

Employing deep learning, a subset of machine learning characterized by neural networks modeled after the human brain, the researchers developed an AI framework that scrutinized retinal morphology. This model was able to discern subtle variations in retinal arteries, veins, and the optic nerve head, features imperceptible to the human eye but correlated strongly with known risk factors for Alzheimer’s disease. Such morphological markers serve as proxies for neurovascular health, which is crucial given Alzheimer’s recognized association with vascular impairment.

One of the most striking revelations of this research was the model’s capacity not only to predict intrinsic biological traits such as sex and blood pressure but also modifiable lifestyle factors that influence Alzheimer’s risk. The AI effectively inferred behaviors like smoking, alcohol consumption, and even insomnia from retinal images alone. This objective measurement circumvents the notorious unreliability of self-reported lifestyle data, often plagued by bias and inaccuracies, thereby enriching risk assessment precision.

As Dr. Fang points out, retinal morphology functions less like a mere clinical questionnaire and more like an integrative biological sensor reflecting a cumulative lifetime burden of neurovascular and lifestyle insults. This conceptual shift underscores the retina’s role in encapsulating decades of physiological data, transforming retinal imaging into a powerful tool for capturing both present health and future vulnerability.

Furthermore, the implications extend beyond risk prediction. Identifying individuals with early signs of retinal changes could trigger timely clinical interventions long before cognitive symptoms manifest. Such preclinical detection enables the implementation of protective lifestyle adjustments, pharmacological therapies, or cognitive training programs designed to delay or mitigate Alzheimer’s progression.

The pioneering work built on previous findings from Fang’s group that demonstrated retinal images’ utility in detecting active Alzheimer’s disease cases. However, this new model pioneers the field by focusing on prodromal markers and risk factors instead of established dementia, bridging a critical gap in neurodegenerative diagnostics.

Importantly, the use of retinal photographs democratizes neurovascular health monitoring. Since retinal imaging is non-invasive, accessible, and affordable, it offers the prospect of integrating brain health assessment into routine eye care, thus expanding preventive neurology beyond specialized clinical settings.

This research also exemplifies the synergy between computational science and biomedical engineering. By combining sophisticated image analysis algorithms with large-scale patient data, it transcends traditional diagnostic constraints, marrying technology with medicine in a profoundly impactful manner.

While challenges remain, including the need for further validation across diverse populations and integration with other biomarkers, this study sets a new paradigm for early Alzheimer’s disease risk stratification. The possibility of preemptive interventions guided by retinal AI analysis heralds a future where the devastating trajectory of Alzheimer’s may be altered through timely and personalized healthcare.

In summary, the novel application of deep learning to retinal photographs opens an unprecedented window into brain health, heralding a new era of precision neurodiagnostics. It moves us closer to the long-sought goal of identifying Alzheimer’s risk decades in advance, fostering opportunities for early intervention and ultimately, better patient outcomes.

Subject of Research: People

Article Title: Prediction of Alzheimer’s disease risk factors from retinal images via deep learning: Development and validation of biologically relevant morphological associations in the UK Biobank

News Publication Date: 16-Jun-2026

Web References:
DOI: 10.1177/13872877261457650

Keywords

Alzheimer’s disease, Neurodegenerative diseases, Neurological disorders, Eye, Retina, Artificial intelligence, Image analysis, Deep learning, Biomedical engineering, Neurovascular integrity, Retinal biomarkers, Predictive modeling

In a groundbreaking development addressing the burgeoning concern of privacy in modern medical technology, researchers at the University of Kansas have unveiled a transformative artificial intelligence (AI) model designed specifically to safeguard sensitive biometric data embedded within electrocardiograms (ECGs). This innovation is poised to reshape how medical institutions share and analyze vital cardiovascular data without compromising patient confidentiality. Electrocardiograms have long been renowned for their role in capturing the heart’s electrical activity to diagnose and monitor cardiac health; however, as AI integration deepens, these signals inadvertently reveal more than just clinical information — exposing personal attributes such as sex, age, race, and even uniquely identifiable biometric markers.

The research team at Kansas, led by doctoral candidate Fairuz Shadmani Shishir in collaboration with the KU Medical Center, has pioneered the privacy-preserving variational autoencoder (PP-VAE). This novel AI architecture is specially engineered to retain the clinical utility of ECG data while systematically obfuscating sensitive biometric features that might otherwise be inferred through advanced AI analysis. The dual objective of PP-VAE is both technically sophisticated and ethically imperative, ensuring that predictive diagnostic accuracy remains uncompromised while minimizing the risk of privacy breaches inherent in sharing raw biomedical signals.

Electrocardiograms, traditionally viewed as a straightforward diagnostic tool, have grown in complexity with modern AI techniques that can extrapolate a multiplicity of patient traits beyond the cardiovascular parameters they were designed to measure. Shishir notes that these advanced systems can uncover “soft biometrics” such as demographic information, which raises pressing data governance and patient privacy challenges. By developing PP-VAE, the researchers aim to reimagine ECG data processing whereby sensitive attributes are masked without degrading the signal quality necessary for important medical prognoses, such as identifying patients at risk of left ventricular ejection fraction (LVEF) abnormalities, a critical indicator linked to heart failure and mortality risk.

The technical underpinning of PP-VAE involves training independent convolutional neural networks to disentangle and suppress identifiable biometric markers while preserving clinically relevant features within the ECG signal. This balancing act required careful engineering to ensure that the encoded ECG data remained diagnostically rich, capable of supporting predictions related to conditions such as left ventricular hypertrophy and forecasting five-year mortality risk. The research showcased that their method consistently outperformed or competed with other state-of-the-art AI models, marking a significant stride in machine learning’s ability to harmonize privacy with clinical efficacy.

Importance of such privacy-preserving strategies becomes particularly clear against the backdrop of the healthcare industry’s increasing reliance on data sharing for collaborative research, AI model development, and multi-institutional patient care coordination. The KU team articulates that unrestricted data sharing without privacy controls introduces tangible risk vectors for patient re-identification and misuse. PP-VAE proposes a scalable approach toward enabling secure exchange of ECG data, thus fostering innovation and improving medical outcomes while staunchly protecting individual privacy rights.

This research also touches on the profound issue of bias within AI-driven medical diagnostics, which has historically contributed to disparities in healthcare delivery among marginalized populations. The team consciously incorporated balanced datasets reflective of gender and racial diversity in their model training to mitigate bias and improve generalized performance across varied demographic groups. While initial validations were primarily conducted using data from KU Medical Center and publicly available datasets, future work is projected to expand this cross-regional training, enhancing the robustness and impartiality of the model when applied globally.

Another compelling facet of this breakthrough is the planned public release of the PP-VAE model, reflecting the researchers’ commitment to transparency, collaboration, and democratization of AI tools in medicine. By allowing institutions worldwide to access and further refine the model with local datasets, the innovation promises to catalyze a new era of secure, privacy-conscious healthcare analytics. Adoption of PP-VAE could alleviate prevalent trust issues among patients concerned about the confidentiality of their biometric health information—a critical barrier to broader acceptance of AI-driven healthcare technologies.

Furthermore, the researchers discuss the broader implications for data-driven diagnosis, illustrating how balancing the protection of sensitive attributes with clinical utility could become a standard principle in biomedical AI applications beyond cardiology. This approach offers a blueprint for addressing ethical and privacy challenges that increasingly pervade the intersection of health data science and artificial intelligence.

The University of Kansas team’s work is also distinguished by its multidisciplinary nature, featuring collaboration between electrical engineering, computer science, and cardiovascular medicine experts. Such an integrated approach enabled the synthesis of advanced machine learning expertise with intimate clinical insight, culminating in a pragmatic solution tailored precisely to real-world healthcare needs.

This pioneering study was recently published in Scientific Reports, showcasing detailed methodology, experimental evaluations, and comparative performance analyses that underscore the efficacy and potential transformative impact of PP-VAE. Supported by the American Heart Association, this research is an exemplar of innovative technological stewardship addressing one of the most pressing challenges in digital health.

As AI continues to proliferate across medical diagnostics, models like PP-VAE will undeniably play a critical role in shaping ethical frameworks and technological architectures for future patient data management. By protecting sensitive biometric identifiers embedded in ECG data, the model not only preserves patient autonomy but also enhances the potential for AI-driven insights to be safely harnessed for better clinical outcomes worldwide.

The journey ahead involves validating and deploying this technology in diverse healthcare environments globally to ensure scalability, efficacy, and fairness remain intact as data heterogeneity increases. Yet, with the foundational work from the University of Kansas, a robust and privacy-conscious approach to ECG analysis and beyond appears well within reach, heralding a new era of secure AI-driven cardiovascular care.

Subject of Research: Privacy-preserving AI models for electrocardiogram data analysis
Article Title: Safeguarding Patient Privacy in Electrocardiogram Analysis with AI-driven Models
Web References: Scientific Reports Article
Image Credits: Fairuz Shadmani Shishir / University of Kansas

Keywords

Privacy-preserving AI, Electrocardiogram (ECG), Variational Autoencoder, Convolutional Neural Networks, Biomedical Data Security, Cardiovascular Diagnostics, Left Ventricular Ejection Fraction, Patient Privacy, Machine Learning Bias, Medical Data Sharing, Artificial Intelligence in Healthcare, Clinical Decision Support

In a remarkable acknowledgment of his contributions to nephrology, Dr. Sushrut S. Waikar has received the American Society of Nephrology (ASN) Distinguished Mentor Award. This prestigious accolade honors individuals who have profoundly impacted the kidney health community through their dedication to mentorship, fostering the careers of emerging clinicians and researchers. Dr. Waikar’s influence extends far beyond routine clinical practice; he has been instrumental in inspiring trainees to dedicate themselves to nephrology, emphasizing innovation in both research and healthcare practice.

Dr. Waikar currently holds the position of Chief of Nephrology at Boston Medical Center and serves as the Norman G. Levinsky Professor of Medicine at Boston University’s Chobanian & Avedisian School of Medicine. As a clinician-scientist, Dr. Waikar has maintained continuous funding from the National Institutes of Health (NIH) for over two decades, highlighting his sustained commitment to advancing kidney disease research. His expansive research agenda incorporates epidemiologic methodologies, translational science, and interventional clinical trials designed to address urgent clinical challenges.

Central to Dr. Waikar’s research portfolio is the refinement of diagnostic tools for kidney diseases, an area critical for early detection and improved patient outcomes. His laboratory has developed novel biomarkers and testing algorithms that aim to enhance diagnostic accuracy, thereby allowing for more timely and precise therapeutic interventions. Such advancements are vital in a field where early-stage kidney dysfunction often goes undetected until it progresses to irreversible damage.

Another significant thrust of Dr. Waikar’s research involves kidney biopsy studies, which offer invaluable insights into the pathophysiological mechanisms underlying disease progression within the renal parenchyma. By analyzing tissue samples, his team seeks to elucidate the cellular and molecular pathways that drive kidney deterioration, providing a foundation for the future design of targeted therapies. This level of detailed study bridges the gap between clinical observation and basic science, enabling a more comprehensive understanding of renal pathology.

Dr. Waikar’s investigations also spotlights a particularly devastating public health concern known as Chronic Kidney Disease of uncertain etiology (CKDu). This disease has emerged as a lethal epidemic primarily afflicting young agricultural workers in Central America and South Asia. Unlike traditional forms of chronic kidney disease associated with diabetes or hypertension, CKDu’s etiology remains elusive and multifactorial. His research endeavors aim to clarify environmental, occupational, and genetic risk factors contributing to this silent crisis, with hopes of informing preventative strategies and policy interventions.

Within the realm of precision medicine, Dr. Waikar acts as principal investigator for the NIH Kidney Precision Medicine Project. This ambitious initiative is engineered to leverage cutting-edge genomic, proteomic, and proteomic technologies to tailor kidney disease treatment at an individual level. By integrating these high-throughput techniques with clinical data, this project aspires to revolutionize management paradigms for kidney disorders, ultimately improving personalized patient care outcomes.

In addition to his leadership in precision medicine, Dr. Waikar coordinates the CKD of Unknown Etiology Consortium, a collaborative network of investigators dedicated to elucidating CKDu. This consortium underscores the importance of multidisciplinary cooperation in tackling complex health challenges, combining epidemiology, environmental sciences, and nephrology to develop holistic solutions to kidney health crises.

Dr. Waikar’s intellectual journey began with an undergraduate education in English and neuroscience at Amherst College, fostering a broad intellectual foundation that supports his interdisciplinary approach. He then earned his medical degree at Yale University, further complementing his scientific expertise with clinical acumen. His postgraduate training in internal medicine and nephrology at highly regarded institutions such as the University of California, San Francisco, and the Mass General Brigham system was distinguished by leadership roles, including chief medical resident, reflecting his early commitment to medical education and mentorship.

His academic trajectory also includes earning a Master’s degree in Public Health from Harvard University, which underpins his rigorous approach to epidemiology and population-based studies. This public health background allows Dr. Waikar to navigate and address the systemic factors impacting kidney health globally, marrying clinical insight with health policy and preventive medicine.

The American Society of Nephrology, founded in 1966, stands as the largest professional society devoted to kidney disease research and education worldwide. To further acknowledge the critical contributions of midcareer professionals, ASN established the Midcareer Awards Program in 2019, celebrating individuals like Dr. Waikar who demonstrate exceptional clinical expertise, innovative research, and dedicated service to the nephrology field and the society’s mission.

Dr. Waikar’s recognition by the ASN Distinguished Mentor Award not only celebrates his individual achievements but also highlights the critical role that mentorship plays in shaping the future of nephrology. His ability to guide, inspire, and cultivate the development of emerging leaders ensures that advances in kidney research and patient care continue to accelerate, ultimately benefiting countless individuals suffering from kidney disease globally.

Through the integration of basic science, clinical application, and public health strategies, Dr. Waikar exemplifies the modern physician-scientist who transforms knowledge into meaningful biomedical progress. His contributions serve as a catalyst for ongoing discoveries and innovations that hold the promise of reducing kidney disease burden worldwide.

Subject of Research:
Kidney disease diagnostics and research, Chronic Kidney Disease of uncertain etiology (CKDu), kidney biopsy studies, precision medicine in nephrology.

Article Title:
Not provided.

News Publication Date:
Not provided.

Web References:
Not provided.

References:
Not provided.

Image Credits:
Not provided.

Keywords:
Nephrology, kidney disease, chronic kidney disease, CKDu, NIH Kidney Precision Medicine Project, kidney biopsy, biomarkers, epidemiology, translational research, mentorship, American Society of Nephrology, public health.